Literature DB >> 9464801

CD40 ligand inhibits Fas/CD95-mediated apoptosis of human blood-derived dendritic cells.

T A Koppi1, T Tough-Bement, D M Lewinsohn, D H Lynch, M R Alderson.   

Abstract

Dendritic cells (DC) are considered to be the most potent antigen-presenting cells (APC) in the immune system. In this study, we analyzed the regulation of apoptosis of human peripheral blood-derived DC. DC were generated from adherent peripheral blood mononuclear cells that had been cultured for 7 days with granulocyte-macrophage colony-stimulating factor and interleukin-4. These cells displayed phenotypic properties of DC, including dendritic processes, expression of CD1a and lack of expression of CD14, and were very potent at presenting soluble antigens to T cells. Blood-derived DC were demonstrated to express the Fas/CD95 antigen and an agonist antibody to CD95 strongly induced apoptotic cell death in these cells. Soluble trimeric CD40 ligand potently inhibited both CD95-mediated and spontaneous apoptosis in DC. The data suggest that interactions between members of the tumor necrosis factor family of ligands expressed by T cells with their receptors on DC play an important role in the regulation of apoptosis in DC during antigen presentation and may, therefore, regulate the duration of T cell expansion and cytokine production.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9464801     DOI: 10.1002/eji.1830271212

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

Review 1.  Local immune responses in afferent and efferent lymph.

Authors:  D M Haig; J Hopkins; H R Miller
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

2.  CD40 signaling in human dendritic cells is initiated within membrane rafts.

Authors:  P O Vidalain; O Azocar; C Servet-Delprat; C Rabourdin-Combe; D Gerlier; S Manié
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

Review 3.  Regulatory role of CD4+ T cells during the development of contact hypersensitivity responses.

Authors:  A V Gorbachev; R L Fairchild
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 4.  Regulation and function of class II major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: Implications in neurological diseases.

Authors:  George M O'Keefe; Vince T Nguyen; Etty N Benveniste
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

Review 5.  Death receptor signaling and autoimmunity.

Authors:  Richard M Siegel; Jagan Muppidi; Margaret Roberts; Melissa Porter; Zhengqi Wu
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

6.  Amplification of Fas-mediated apoptosis in type II cells via microdomain recruitment.

Authors:  Patrick Legembre; Sophie Daburon; Patrick Moreau; François Ichas; Francesca de Giorgi; Jean-François Moreau; Jean-Luc Taupin
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

7.  CD4 T cell-induced, bid-dependent apoptosis of cutaneous dendritic cells regulates T cell expansion and immune responses.

Authors:  Sanjay Pradhan; Joseph Genebriera; Warren L Denning; Kumar Felix; Craig A Elmets; Laura Timares
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

8.  CD40 is expressed and functional on neuronal cells.

Authors:  Jun Tan; Terrence Town; Takashi Mori; Demian Obregon; Yajuan Wu; Anthony DelleDonne; Amyn Rojiani; Fiona Crawford; Richard A Flavell; Mike Mullan
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

9.  Dendritic cells rapidly undergo apoptosis in vitro following culture with activated CD4+ Valpha24 natural killer T cells expressing CD40L.

Authors:  M Nieda; A Kikuchi; A nicol; Y Koezuka; Y Ando; S Ishihara; N Lapteva; T Yabe; K Tokunaga; K Tadokoro; T Juji
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

Review 10.  Gene-modified dendritic cells for immunotherapy against cancer.

Authors:  Andreas Lundqvist; Pavel Pisa
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.